Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. GMRE
GMRE logo

GMRE Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Global Medical REIT Inc (GMRE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
--
1 Day change
-0.03%
52 Week Range
45.750
Analysis Updated At
2026/02/20
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Global Medical REIT Inc (GMRE) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. While there is insider buying and the stock shows some bullish moving averages, the company's financial performance is weak with significant declines in net income and EPS. Additionally, there are no strong trading signals or positive news catalysts to support a buy decision at this time.

Technical Analysis

The technical indicators show mixed signals. The MACD is negative and expanding downward, suggesting bearish momentum. RSI is neutral at 48.029, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 35.686, and resistance is at 37.336. The stock is trading near its support level.

Options Data

Bullish
Open Interest Put-Call Ratio
Neutral
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
1
Buy
2

Positive Catalysts

  • Insider buying has increased significantly by 4132.36% over the last month, indicating confidence from insiders.

Neutral/Negative Catalysts

  • The company's financials show a significant decline in net income (-435.06% YoY) and EPS (-421.43% YoY). No recent news or Congress trading data is available to act as a positive catalyst.

Financial Performance

In Q3 2025, revenue increased by 8.65% YoY to $37,229,000. However, net income dropped significantly to -$6,001,000 (-435.06% YoY), and EPS fell to -0.45 (-421.43% YoY). Gross margin remained flat at 100%. Overall, the financial performance is weak.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes are provided in the data.

Wall Street analysts forecast GMRE stock price to rise
1 Analyst Rating
Wall Street analysts forecast GMRE stock price to rise
0 Buy
1 Hold
0 Sell
Hold
Current: 35.980
sliders
Low
41
Averages
41
High
41
Current: 35.980
sliders
Low
41
Averages
41
High
41
Baird
Neutral
downgrade
$45 -> $41
AI Analysis
2025-11-11
Reason
Baird
Price Target
$45 -> $41
AI Analysis
2025-11-11
downgrade
Neutral
Reason
Baird lowered the firm's price target on Global Medical REIT to $41 from $45 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results which suggest the tough capital markets may lead to asset recycling.
Alliance Global Partners
Gaurav Mehta
Buy
downgrade
2025-05-29
Reason
Alliance Global Partners
Gaurav Mehta
Price Target
2025-05-29
downgrade
Buy
Reason
Alliance Global Partners analyst Gaurav Mehta lowered the firm's price target on Global Medical REIT to $8.50 from $9.50 and keeps a Buy rating on the shares. The company lowered its common dividend by 28.6%, which is the "right step" given the prior dividend was not covered by 2025 and 2026 estimates, the analyst tells investors in a research note. Going forward, the firm believes improved portfolio performance, including an improvement in occupancy, resolving of tenant issues such as Prospect Medical and the closure of the CEO search could be a positive catalyst for the stock.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GMRE
Unlock Now

People Also Watch